CD8A and neoplasm: In both clinical trials, antigen-loaded pDCs were found to effectively induce B and CD8+ T cell anti-tumor-specific responses in patients, while being well-tolerated and safe (grade 1–2 toxicities) (Tel, 2013; Westdorp, 2019).